Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04096391 · ClinicalTrials.gov registry record · NA

Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population

A NA study of Pain, Chronic and Pain, Intractable, sponsored by Evolve Restorative Center.

Completed
Registry status
NA
Development phase
73
Enrollment target
1
Study location

NCT04096391: Completed NA study of Pain, Chronic and Pain, Intractable, sponsored by Evolve Restorative Center.

NCT04096391 is a NA study of Pain, Chronic and Pain, Intractable that has completed, run by Evolve Restorative Center. The registered enrollment target is 73 participants, below the 720-participant average among 48 other Pain, Chronic trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04096391, a NA study of Pain, Chronic and Pain, Intractable, has completed, sponsored by Evolve Restorative Center.

COMPLETED
Registry status
NA
Development phase
73 participants
Enrollment target
1
Study location

Study Summary

This study is being conducted to compare intrathecal morphine using the commercially available intrathecal drug delivery systems (IDDS), and conventional medical management (CMM) in subjects with non-cancer, refractory chronic pain.

Primary Outcome

The Numeric Pain Rating Scale (NPRS) is a 0-10 numeric pain rating scale (11 point scale), where a higher scores equates to more pain. The primary endpoint for this post-marketing study is the comparison of the NPRS between the IDDS group and the CMM group collected in the Study Diary at various time points.

Interventions

  • DEVICE Flowonix Prometra® II Programmable Infusion System
  • DRUG Pain Medicine

Study Locations (1)

California

  • Evolve Restorative Center - Santa Rosa

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2019-06-05
Est. Completion 2022-04-11
Phase NA
Evolve Restorative Center

1 total trials

What the finished NCT04096391 record still lists

NCT04096391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 720-participant average among 48 other Pain, Chronic trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Pain, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Flowonix Prometra® II Programmable Infusion System is the first listed.

NCT04096391 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04096391 about?

NCT04096391 is a clinical study titled "Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population". This study is being conducted to compare intrathecal morphine using the commercially available intrathecal drug delivery systems (IDDS), and conventional medical management (CMM) in subjects with non-cancer, refractory chronic pain.

What is the current status of trial NCT04096391?

This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2019-06-05. Estimated completion is 2022-04-11.

What conditions does trial NCT04096391 study?

This clinical trial studies the following conditions: Pain, Chronic, Pain, Intractable, Chronic Nonmalignant Pain.

What interventions are being tested in trial NCT04096391?

The interventions under investigation include: Flowonix Prometra® II Programmable Infusion System (DEVICE), Pain Medicine (DRUG).

Who is sponsoring clinical trial NCT04096391?

This trial is sponsored by Evolve Restorative Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04096391 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04096391's enrollment target sits among peer trials

73 29th of 48 higher than 20 of 48 other Pain, Chronic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04096391, the US trial registry maintained by the National Library of Medicine. NCT04096391 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.